|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.74 CAD | +0.34% |
|
+1.66% | +15.79% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 168M 119M 105M 97.46M 89.43M 11.49B 171M 1.16B 452M 5.65B 448M 438M 19.53B | P/E 2026 * |
16.5x | P/E 2027 * | 13.6x |
|---|---|---|---|---|---|
| Enterprise Value | 168M 119M 105M 97.46M 89.43M 11.49B 171M 1.16B 452M 5.65B 448M 438M 19.53B | EV / Sales 2026 * |
2.44x | EV / Sales 2027 * | 2.04x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | +0.34% | ||
| 1 week | +1.66% | ||
| Current month | +1.66% | ||
| 1 month | +5.29% | ||
| 3 months | -0.07% | ||
| 6 months | +10.08% | ||
| Current year | +15.79% |
| 1 week | 14.5 |  | 14.75 |
| 1 month | 13.9 | | 14.75 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.45 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/26 | Tax | Executive/Senior Manager | -11,359 | 0.0993% | ||
| 6/30/26 | Option | Director | -376 | 0.0033% | ||
| 6/30/26 | Option | -600 | 0.0052% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.34% | +1.66% | +28.85% | +95.23% | 119M | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +7.09% | +35.90% | +29.32% | 341B | |
| -0.60% | +2.95% | +36.28% | +39.04% | 297B | |
| -0.14% | +0.33% | +18.70% | +17.64% | 262B | |
| +0.09% | -4.53% | -27.60% | -42.19% | 215B | |
| +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| Average | +0.36% | +0.83% | +26.80% | +56.08% | 361.41B | |
| Weighted average by Cap. | +0.56% | +1.57% | +36.19% | +77.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49M 43.03M 40.02M 36.72M 4.72B 70.06M 475M 186M 2.32B 184M 180M 8.02B | 82.3M 58.44M 51.33M 47.73M 43.8M 5.63B 83.57M 567M 221M 2.77B 219M 215M 9.57B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-24 | $14.74 | +0.34% | 907 |
| 26-07-23 | $14.69 | +1.03% | 1,800 |
| 26-07-22 | $14.54 | -1.09% | 8,087 |
| 26-07-21 | $14.70 | +1.38% | 3,046 |
| 26-07-20 | $14.50 | 0.00% | 5,882 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.69CAD
Average target price
18.00CAD
Spread / Average Target
+22.53%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
